M. Duong

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

I. Thompson, C. Tangen, N. Agarwal, 2020, Prostate Cancer and Prostatic Diseases.

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Namita S. Gandhi, P. Philip, A. Lowy, 2021, JAMA oncology.

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Namita S. Gandhi, P. Philip, A. Lowy, 2020 .

Surgical Outcome Results From SWOG S1505

P. Philip, A. Lowy, E. Chiorean, 2020, Annals of surgery.

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

J. Berlin, P. Philip, E. Swisher, 2021, Clinical Cancer Research.

Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001.

P. Philip, M. Pishvaian, A. Lowy, 2021 .

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

I. Thompson, C. Tangen, N. Agarwal, 2020, Prostate Cancer and Prostatic Diseases.